Literature DB >> 8578797

Adenovirus vectors as recombinant viral vaccines.

J L Imler1.   

Abstract

Adenoviruses can efficiently induce immunity in the lung following single enteric delivery. These viruses can also be engineered to express a number of heterologous proteins in vitro. In the past 10 years, recombinant adenoviruses expressing a variety of antigens have been constructed and tested. This article reviews the main properties of adenoviruses which render them attractive for vaccine development, as well as the results of the immunization studies performed to date. Some disadvantages of this technology and the desired characteristics of second generation adenoviral vectors are discussed.

Mesh：

Substances：

Year:  1995        PMID： 8578797     DOI： 10.1016/0264-410x(95)00032-v

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  Recombinant adenovirus-mediated expression of GHS-R1a in HEK 293 cells.

Authors:  Li Liu; Hua-Min Xu; Hong Jiang; Jun Wang; Ning Song; Jun-Xia Xie
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

3.  The Gordon Wilson lecture: using genetic medicine to regenerate diseased organs and protect against the hostile environment.

Authors:  Timothy P O'Connor; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

4.  Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice.

Authors:  K Tsukamoto; P Smith; J M Glick; D J Rader
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

5.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

6.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Authors:  S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White
Journal:  J Natl Cancer Inst       Date:  1998-12-16       Impact factor: 13.506

7.  Nucleotide sequence, genome organization, and transcription map of bovine adenovirus type 3.

Authors:  P S Reddy; N Idamakanti; A N Zakhartchouk; M K Baxi; J B Lee; C Pyne; L A Babiuk; S K Tikoo
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Experimental inoculation of heifers with bovine adenovirus type 3.

Authors:  S K Mittal; S K Tikoo; J Van Donkersgoed; T Beskorwayne; D L Godson; L A Babiuk
Journal:  Can J Vet Res       Date:  1999-04       Impact factor: 1.310

9.  Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth.

Authors:  D W Liu; Y P Tsao; C H Hsieh; J T Hsieh; J T Kung; C L Chiang; S J Huang; S L Chen
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

10.  Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion.

Authors:  R E Toes; R C Hoeben; E I van der Voort; M E Ressing; A J van der Eb; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.